3
Announcements
Trials
Browse
Landscape
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Sarcoma
1
Rectal Neoplasms
1
Lung Neoplasms
1
Liver Neoplasms
1
Head and Neck Neoplasms
1
Colonic Neoplasms
1
Breast Neoplasms
1
Anus Neoplasms
1
Interventions
pembrolizumab
7
Cetuximab
5
selpercatinib
3
cemiplimab
3
Trastuzumab
3
Magnetic Resonance Spectroscopy
3
Gemcitabine
3
Erlotinib Hydrochloride
3
Bortezomib
3
sargramostim
2
motexafin gadolinium
2
entinostat
2
Specimen Handling
2
Radiotherapy
2
Oxaliplatin
2
Irinotecan
2
Fluorodeoxyglucose F18
2
Drug Therapy
2
Docetaxel
2
Biopsy
2
ulixertinib
1
tumor necrosis factor-alpha, CNGRC fusion protein, human
1
trastuzumab deruxtecan
1
trastuzumab biosimilar HLX02
1
trametinib
1
tislelizumab
1
tipifarnib
1
tanespimycin
1
spartalizumab
1
serabelisib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Colonic Neoplasms
×
Radionuclide Imaging
×
Head & Neck
×
Clear all
NCT06904365
2026-05-18
OvAR-Y
Washington University School of Medicine
Active not recruiting
10 enrolled